MyFinsight
Home
Blog
About
Contact
Download
Download image
Net decrease in
cash, cash...
-$68,544K
Proceeds from the
issuance of common...
$6,197K
Accounts payable
$2,987K
Stock-based compensation
expense
$2,461K
Non-cash interest
expense
$2,288K
Depreciation expense
$1,342K
Accrued expenses
$957K
Amortization expense
$523K
Non-cash operating lease
costs
$15K
Net cash provided by
financing activities
-$44,591K
Net cash used in
operating activities
-$23,904K
Net cash used in
investing activities
-$49K
Canceled cashflow
$6,197K
Canceled cashflow
$10,573K
Partial call payment
under amended revenue...
$50,000K
Net loss
-$17,510K
Inventory
$7,302K
Purchase of property and
equipment
$49K
Payments of finance lease
principal
$743K
Revenue interest
payments
$45K
Change in fair value of
contingent earnout...
-$4,893K
Change in fair value of
derivatives
$4,009K
Accounts receivable
$684K
Prepaid expenses and
other current assets
$64K
Operating lease
obligation
-$15K
Back
Back
Cash Flow
source: myfinsight.com
Humacyte, Inc. (HUMAW)
Humacyte, Inc. (HUMAW)